miR-28 is a regulator of the Germinal Center reaction that dampens BCR signaling and impairs B cell proliferation and survival.
miR-28 has anti-tumoral activity in Burkitt and Diffuse Large B Cell lymphomas.
Non-Hodgkin Lymphoma (NHL) comprises a variety of neoplasms, many of which arise from germinal center (GC)-experienced B cells. microRNA-28 (miR-28) is a GC-specific microRNA whose expression is lost in numerous mature B cell neoplasms. Here we show that miR-28 regulates the GC reaction in primary B cells by impairing CSR and memory B and plasma cell differentiation. Deep quantitative proteomics combined with transcriptome analysis identified miR-28 targets involved in cell cycle and B cell receptor signaling. Accordingly, we found that miR-28 expression diminished proliferation in primary and lymphoma cells in vitro. Importantly, miR-28 re-expression in human Burkitt (BL) and Diffuse Large B cell lymphoma (DLBCL) xenografts blocked tumor growth, both when delivered in viral vectors or as synthetic, clinically amenable, molecules. Further, the antitumoral effect of miR-28 is conserved in a primary murine in vivo model of BL. Thus, miR-28 replacement is uncovered as a novel therapeutic strategy for DLBCL and BL treatment.
- Submitted August 1, 2016.
- Accepted February 1, 2017.
- Copyright © 2017 American Society of Hematology
To view this item, select one of the options below.
If you already have a subscription, you may gain access using your ASH username and password.
Log in through your institution
Subscribe to the Journal - Subscribe to the print and/or online journal.